Trial Profile
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Acronyms CHERISH
- Sponsors Biogen; Ionis Pharmaceuticals
- 22 Apr 2021 Results (n=75) assessing association between plasma phosphorylated neurofilament heavy chain (pNF-H) levels and clinical motor function endpoints in nusinersen-treated individuals with later-onset spinal muscular atrophy (SMA) in patients participated in the CHERISH/SHINE studies, presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 19 Apr 2021 According to a Biogen media release, data from this study is being presented at the Biogen Media Release.
- 19 Apr 2021 Results published in the Biogen Media Release